Author Archives: Patricia Inacio PhD

Two newly reported mutations in a complement-related gene appear to have triggered atypical hemolytic uremic syndrome (aHUS) in a woman within months of a kidney transplant, according to a case report. The report, “A novel Atypical hemolytic uremic Syndrome–Associated CFH gene in a renal transplant recipient complicated with ileum perforation,”…

Plasma exchange and treatment with Soliris (eculizumab) may be used successfully to treat pregnancy-related atypical hemolytic uremic syndrome (aHUS) complicated by kidney failure, a case report suggests. The report, “Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review,” was published in…

A 57-year old man developed atypical hemolytic uremic syndrome (aHUS) after being bitten by a pit viper belonging to the Bothrops aspe species, a recent case report suggests. According to its authors, this is the first report describing an association between aHUS and this viper species, likely triggered by venom-induced…

Soliris (eculizumab), given as a treatment or as a preventive measure, reduces disease relapse and kidney transplant loss in people with atypical hemolytic uremic syndrome (aHUS), according to a Brazilian retrospective study. Researchers emphasized the need, in low- to medium-income countries, to provide greater access to Soliris and similar…

Atypical hemolytic uremic syndrome (aHUS) can co-exist with severe combined immunodeficiency (SCID), a rare genetic disorder characterized by a weakened immune system, a case report noted. Prompt diagnosis is crucial to improving patient outcomes, its researchers wrote, especially as the two diseases “are considered to exacerbate each other.” The…

Treatment with Soliris (eculizumab) may be discontinued with close monitoring in people with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission for at least six months — providing their kidney function remains stable — or in those who have developed end-stage kidney disease, a small study…

Soliris (eculizumab) was shown to effectively treat atypical hemolytic uremic syndrome (aHUS) triggered by COVID-19 in a patient who had undergone a heart transplant five years earlier, according to a recent case report study. “We present a case of [a] 32-year-old Hispanic male with a history of heart…

Infection with SARS-CoV-2, the virus that causes COVID-19, may trigger first clinical symptoms or relapse of atypical hemolytic uremic syndrome (aHUS) in people carrying mutations in complement genes, a case report suggests. The report, “Atypical HUS triggered by infection with SARS-CoV2,” was published in the journal…

Family members of people with atypical hemolytic uremic syndrome (aHUS) who carry mutations in complement genes may be at a lower risk of developing this disease than previously reported, according to an Italian study. The single-center study estimated the risk to be at 20% — much lower than the 50%…

A 6-month-old girl who was diagnosed with cystic fibrosis (CF) went into kidney failure due to atypical hemolytic uremic syndrome (aHUS), according to scientists who worked on her case report. Her kidney function was completely restored following hemodialysis, plasma exchange therapy — a form of treatment that replaces…